Assenagon Asset Management S.A. Reduces Holdings in Zoetis Inc. $ZTS

Assenagon Asset Management S.A. decreased its position in shares of Zoetis Inc. (NYSE:ZTS) by 50.0% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 815,412 shares of the company’s stock after selling 816,207 shares during the period. Assenagon Asset Management S.A.’s holdings in Zoetis were worth $96,390,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Brighton Jones LLC lifted its holdings in shares of Zoetis by 180.4% in the 4th quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock worth $754,000 after acquiring an additional 2,978 shares during the last quarter. Empowered Funds LLC grew its holdings in Zoetis by 6.2% during the 1st quarter. Empowered Funds LLC now owns 11,293 shares of the company’s stock valued at $1,859,000 after purchasing an additional 657 shares during the last quarter. Intech Investment Management LLC raised its position in Zoetis by 17.2% in the 1st quarter. Intech Investment Management LLC now owns 8,347 shares of the company’s stock worth $1,374,000 after purchasing an additional 1,224 shares during the period. Sivia Capital Partners LLC raised its position in Zoetis by 73.8% in the 2nd quarter. Sivia Capital Partners LLC now owns 3,348 shares of the company’s stock worth $522,000 after purchasing an additional 1,422 shares during the period. Finally, Glenview Trust co lifted its stake in Zoetis by 11.8% in the second quarter. Glenview Trust co now owns 4,780 shares of the company’s stock worth $745,000 after purchasing an additional 506 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have issued reports on ZTS shares. Leerink Partners restated a “market perform” rating on shares of Zoetis in a research report on Tuesday, March 10th. Stifel Nicolaus dropped their price objective on Zoetis from $105.00 to $95.00 and set a “hold” rating for the company in a report on Friday, May 22nd. Argus reaffirmed a “hold” rating on shares of Zoetis in a research report on Wednesday, May 27th. Citigroup reduced their target price on Zoetis from $145.00 to $112.00 and set a “buy” rating on the stock in a research note on Monday, May 18th. Finally, Morgan Stanley reiterated an “overweight” rating and set a $115.00 target price on shares of Zoetis in a research report on Friday, May 15th. Six equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $133.92.

Insider Activity

In related news, Director Frank A. Damelio acquired 6,650 shares of the company’s stock in a transaction that occurred on Wednesday, May 13th. The shares were bought at an average price of $75.39 per share, with a total value of $501,343.50. Following the completion of the transaction, the director directly owned 21,458 shares in the company, valued at $1,617,718.62. This trade represents a 44.91% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Paul Bisaro purchased 2,000 shares of the stock in a transaction dated Wednesday, May 13th. The stock was purchased at an average price of $75.88 per share, for a total transaction of $151,760.00. Following the completion of the acquisition, the director directly owned 27,862 shares in the company, valued at approximately $2,114,168.56. This represents a 7.73% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders acquired 11,650 shares of company stock worth $886,384. 0.22% of the stock is currently owned by corporate insiders.

Zoetis Price Performance

Shares of ZTS stock opened at $78.14 on Thursday. Zoetis Inc. has a twelve month low of $72.38 and a twelve month high of $161.77. The company has a current ratio of 3.15, a quick ratio of 1.91 and a debt-to-equity ratio of 2.80. The stock has a fifty day simple moving average of $90.47 and a two-hundred day simple moving average of $111.48. The stock has a market capitalization of $32.76 billion, a price-to-earnings ratio of 12.96, a P/E/G ratio of 1.20 and a beta of 0.75.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, May 7th. The company reported $1.53 EPS for the quarter, missing the consensus estimate of $1.60 by ($0.07). The firm had revenue of $2.26 billion for the quarter, compared to analysts’ expectations of $2.30 billion. Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The business’s quarterly revenue was up 2.9% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.48 EPS. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, analysts predict that Zoetis Inc. will post 6.88 EPS for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be issued a $0.53 dividend. The ex-dividend date is Monday, July 20th. This represents a $2.12 annualized dividend and a dividend yield of 2.7%. Zoetis’s payout ratio is currently 35.16%.

Key Stories Impacting Zoetis

Here are the key news stories impacting Zoetis this week:

• Negative Sentiment: Multiple law firms announced or promoted class action lawsuits against Zoetis, with claims covering investors who bought shares between January 14, 2025 and May 6, 2026 and a lead-plaintiff deadline of July 27, 2026. The complaints allege investors were harmed by misleading disclosures about weakening veterinarian adoption and prescription trends. Article: Lost Money on Zoetis Inc. (ZTS)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky
• Negative Sentiment: A shareholder securities fraud lawsuit has already been filed, adding legal overhang and potentially increasing costs, management distraction, and headline risk for the stock. Article: SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Zoetis Inc. (ZTS)
• Neutral Sentiment: Zoetis was also mentioned in a broader healthcare momentum screen and brokerage commentary showing a “Hold” consensus, which suggests sentiment is cautious but not clearly improving. Article: 10 large and mega-cap U.S. healthcare stocks with the weakest momentum grades

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.